Navigation Links
China Biologic Products Commences Trading on OTC Bulletin Board
Date:3/4/2008

TAI'AN CITY, China, March 4 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP," or "the Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on February 29, 2008, it's common stock was approved for quotation on the Over-the-Counter Bulletin Board (the "OTCBB") maintained by the Financial Industry Regulatory Authority (FINRA).

"We are pleased to have our stock quoted on the OTCBB," said Mr. Stanley Wong, CEO of China Biologic Products. "This is an important milestone for us as we seek to expand our list of potential investors and increase both our liquidity and visibility in the market."

The Company's stock is now trading under the symbol CBPO.OB.

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to expand its list of potential investors and increase its liquidity and visibility in the market or otherwise achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Stanley Wong, CEO

China Biologic Products, Inc.

Tel: +86-538-620-2306

Email: IR@chinabiologic.com

Investor Relations Contact:

Mr. Crocker Coulson, President

CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
2. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
3. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
4. China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group
5. China Pharma Appoints Three Independent Non-Executive Directors
6. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
7. AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities
8. China Agro-Technology Appoints New CEO
9. Historic Breakthrough in Fighting Childrens Batten Disease as China Stem Cells Give New Lease on Life to 6 Year Old California Boy
10. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... Assessing Developers and Producers of Those Competitor Biologics  ... to Companies, Activities and Prospects ,  Who ... companies? And what are their sales potentials? Discover, ... you see results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... , May 2, 2016 Q ... its technology partner Mannin Research Inc. will be attending ... which takes place from May 1-5, 2016 in ... be meeting with its vendors and research partners. The ... development goals and other collaborative opportunities for the MAN-01 ...
(Date:4/29/2016)... ... 30, 2016 , ... The MIT bioLogic design team has won multiple ... bacterial properties can be applied to fabric and formed into living interfaces between body ... to humidity change. The team harvested Natto cells and applied them to fabric with ...
(Date:4/29/2016)... ... April 29, 2016 , ... During a two ... into a viable company, CereScan’s CEO, John Kelley, joined other Denver business leaders ... and mentor in the Denver area business community, shared his top fundamental learnings ...
Breaking Biology Technology:
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
(Date:3/15/2016)... , March 15, 2016 Yissum ... , the technology-transfer company of the Hebrew University, announced ... of remote sensing technology of various human biological indicators. ... raising $2.0 million from private investors. ... based on the detection of electromagnetic emissions from sweat ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):